東陽光藥(01558.HK)一季度實現營收1.02億元
格隆匯 4 月 29日丨東陽光藥(01558.HK)公佈,截至2021年3月31日止第一季度,公司營業收入為人民幣1.02億元,同比減少94.91%;歸屬於公司權益持有人的溢利及全面收益總額(不考慮可轉換債券影響)為人民幣負1.32億元,去年同期則為人民幣8.75億元;歸屬於公司權益持有人的溢利及全面收益總額(考慮可轉換債券影響)為人民幣負2.07億元,去年同期則為7.81億元。
截至2021年3月31日止三個月,由於受到新型冠狀病毒肺炎疫情影響,各等級醫院等醫療機構人流量下降,導致公司核心產品可威銷量隨之下降。隨着中國國內疫情得到控制,門診數量逐漸提升,以及集團在藥店、互聯網等渠道的開發與拓展,預計未來集團核心產品銷量將逐漸恢復。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.